GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

TDSPharm Co 464280.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

4,000

-4.99%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About TDSPharm Co

Its shares trade on KOSDAQ under the ticker 464280.KQ. It has been listed since 21 August 2024. In the fiscal year to 31 December 2025, it reported revenue of ₩27.62bn and net income of ₩4.27bn. At that date it held total assets of ₩54.15bn and shareholders' equity of ₩42.78bn.

TDSPharm Co Ltd is a KR-based company operating in industry. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2024-08-21. TDSPharm Co Ltd is a Korea-based company principally engaged in the manufacture and sale of medicine. The firm is mainly engaged in the manufacture and sale of displays for synthetic drugs and other finished drugs. The firm is also engaged in the e-commerce business. In addition, the Company is engaged in the sale of medical equipment.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
21 Aug 2024
Employees
90

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • TDSPharm Co Ltd manufactures synthetic drug displays and finished drugs in Korea.
  • The company employs 90 full-time employees in Seongnam, Gyeonggi-Do.
  • TDSPharm Co Ltd has an e-commerce business for medical equipment sales.

Weaknesses

  • TDSPharm Co Ltd has a limited workforce of 90 employees.
  • The company's IPO was recently on 21 August 2024.
  • TDSPharm Co Ltd operates in a highly regulated pharmaceutical industry.

Opportunities

  • TDSPharm Co Ltd can expand its e-commerce business for medical equipment sales.
  • The company can leverage its synthetic drug manufacturing expertise in Korea.
  • TDSPharm Co Ltd can grow in the Korean pharmaceutical market segment.

Threats

  • TDSPharm Co Ltd faces competition from established pharmaceutical companies in Korea.
  • The company must comply with strict pharmaceutical regulations in Korea.
  • TDSPharm Co Ltd is vulnerable to market fluctuations in the Korean healthcare sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.